|

UPDATE ON HIV AND SARS-CoV-2: TWO PANDEMIC INFECTIONS

{{ getTitle(live) }}

{{ toDate(live.liveStartDate) }}

{{ toTime(live.liveStartDate) }} - {{ toTime(live.liveEndDate) }}

{{ getNotification(live) }}

{{ getButton(live) }}

Programme

COVID-19 PATHOGENESIS

Chaired by Steven Callens & Guido Vanham
09.00 - 09.05 Welcome and Introduction
Linos Vandekerckhove, Ghent University Hospital, Ghent, Belgium
   
09.05 - 09.30 COVID-19 pandemic: a tale of a bat virus from China that changed Belgian history
Steven Van Gucht, Sciensano, Brussels, Belgium
Q&A
   
09.30 - 09.55 SARS-CoV-2 spread through the human body
Jolien Van Cleemput, Ghent University, Ghent, Belgium
Q&A
   
09.55 - 10.20 Poster Presentations:
 
  • External validation of 10 clinical scores for prediction of mechanical ventilation and 90-day mortality in patients admitted with COVID-19 | Gil Verschelden, CUB and ULB, Brussels, Belgium
   
 
  • TGF-β2 is associated with asymptomatic/mild SARS-CoV-2 infection during pregnancy | Susan Pereira Ribeiro, Emory University, Atlanta, GA, USA
   
 
  • Artificial intelligence predicts severity of COVID-19 based on correlation of exaggerated monocyte activation, excessive organ damage and hyperinflammatory syndrome | Olga Vershinina , Institute of Information Technology, Mathematics and Mechanics, National Research Lobachevsky State University of Nizhniy Novgorod, Russia
   
 
  • Novel CRISPR-Cas13d system to target highly conserved sequences of SARS-CoV-2 and other human coronaviruses | Mouraya Hussein, University of Amsterdam, Amsterdam, The Netherlands
   
 
  • Investigation of nosocomial outbreaks of SARS-CoV-2 at a University Hospital using whole genome sequencing | Laurens Lambrechts, Ghent University, Ghent, Belgium
   
10.20 - 10.45 Break and posterviewing
   

COVID-19 VACCINATION

Chaired by Sarah Gerlo & Bert Schepens
10.45 - 11.10 Response of SARS-CoV-2 vaccination towards variants
Steven Callens, Ghent University Hospital, Ghent, Belgium
Q&A
   
11.10 - 11.35 Antibody-based treatments to prevent and tackle SARS-CoV-2 infections
Delphine Acar, Ghent University Hospital, Ghent, Belgium
Q&A
   
11.35 - 12.00 Poster Presentations:
 
  • COVID-19 vaccination with BNT162b2 and ChAdOx1 vaccines has the potential to induce nasal neutralizing antibodies | Jozefien Declercq, Ghent University and VIB, Ghent, Belgium
   
 
  • COVID-19 transmission within a cluster of Belgian students: epidemiological and clinical characteristics and their implications on future response and vaccination strategies | Febe Magherman & Aron Walraevens , Ghent University, Ghent, Belgium
   
 
  • The Neutralizing Activity of convalescent plasma from patients infected with the B.1 SARS-CoV-2 strain drops against the Beta variant and is highly diverse against the other Variants of Concern | Danielle Perez Bercoff, Luxembourg Institute of Health, Esch-sur-Alzette, Luxembourg
   
 
  • Comparing anti-S1 antibody titers in cancer patients after BNT162B2 or ChAdOx1 COVID-19 vaccination | Yana Debie, University Hospital Antwerp, Edegem, Belgium
   
12.00 - 13.00 Break/Satellite Symposia
   

HIV RESERVOIR

Chaired by Jozefien De Clercq & Marion Pardons
13.00 - 13.25 Spatial Approaches to Identify and Characterize HIV Reservoirs
Jacob Estes, Oregon Health and Science University, Oregon, US
Q&A
   
13.25 - 13.50 Next generation multiplex assays for assessment of HIV intactness
Linos Vandekerckhove, Ghent University and Ghent University Hospital, Ghent, Belgium
Q&A
   
13.50 - 14.15 Poster Presentations:
 
  • Dynamics of inflammatory mediators and their clinical correlates following early treated acute HIV infection | Jozefien De Clercq, Ghent University and Ghent University Hospital, Ghent, Belgium
   
 
  • Multiplex assays in dPCR for the quantification of the HIV-1 reservoir | Willem Van Snippenberg, Ghent University, Ghent, Belgium
   
 
  • Chimeric proviral/human transcription events at the bach2 integration locus in cellular models for chronic HIV infection | Ulrike Lange, University Medical Center Hamburg-Eppendorf, Hamburg, Germany
   
14.15 - 14.30 Break and posterviewing
   

HIV CURE

Chaired by Wojciech Witkowski & Jolien Van Cleemput
14.30 - 14.55 The use of bNAbs towards an HIV cure
Sarah Fidler, Imperial College London, London, UK
Q&A
   
14.55 - 15.20 Engineering the immune system for HIV Cure
Paula Cannon, University of Southern California, California, US
Q&A
   
15.20 - 15.45 Poster Presentations:
 
  • Novel NK activating multimeric immunotherapeutic compleXes (NaMix) induce cytotoxic activity against HIV-1 infected cells in vitro and in vivo | Carole Devaux, Luxembourg Institute of Heatlh, Esch-sur Alzette, Luxembourg
         
 
  • HYBRID CAR-T cell secreted antibodies neutralize HIV | Wojciech Witkowski, Ghent University, Ghent, Belgium
   
 
  • Real-life patient-reported outcomes among people living with HIV on single- versus multi-tablet regimens | Sophie Degroote, Ghent University Hospital, Ghent, Belgium
   
15.45 - 16.00 Closing 
  Linos Vandekerckhove, Ghent University and Ghent University Hospital, Ghent, Belgium

Instructors

Linos Vandekerckhove

Linos Vandekerckhove

Head of the HIV Cure Research Center, Ghent University Hospital, Belgium

Jolien Van Cleemput

Jolien Van Cleemput

Ghent University Hospital, Belgium

Guido Vanham

Guido Vanham

Institute of Tropical Medicine and the University of Antwerp, Antwerp, Belgium

Jacob Estes

Jacob Estes

Oregon Health and Science University, Oregon, US

Paula Cannon

Paula Cannon

University of Southern California, California, US

Sarah Fidler

Sarah Fidler

Imperial College London, London, UK

Steven Van Gucht

Steven Van Gucht

Sciensano, Brussels, Belgium

Steven Callens

Steven Callens

 Ghent University Hospital, Ghent, Belgium

Delphine Acar

Delphine Acar

Ghent University Hospital, Belgium

Sarah Gerlo

Sarah Gerlo

Ghent University, Ghent, Belgium

Marion Pardons

Marion Pardons

Ghent University, Belgium

Wojciech Witkowski

Wojciech Witkowski

Ghent University, Ghent, Belgium

Jozefien De Clercq

Jozefien De Clercq

Ghent University , Ghent, Belgium

Bert Schepens

Bert Schepens

VIB-Ghent University, Ghent, Belgium

 

Programme

COVID-19 PATHOGENESIS

Chaired by Steven Callens & Guido Vanham
09.00 - 09.05 Welcome and Introduction
Linos Vandekerckhove, Ghent University Hospital, Ghent, Belgium
   
09.05 - 09.30 COVID-19 pandemic: a tale of a bat virus from China that changed Belgian history
Steven Van Gucht, Sciensano, Brussels, Belgium
Q&A
   
09.30 - 09.55 SARS-CoV-2 spread through the human body
Jolien Van Cleemput, Ghent University, Ghent, Belgium
Q&A
   
09.55 - 10.20 Poster Presentations:
 
  • External validation of 10 clinical scores for prediction of mechanical ventilation and 90-day mortality in patients admitted with COVID-19 | Gil Verschelden, CUB and ULB, Brussels, Belgium
   
 
  • TGF-β2 is associated with asymptomatic/mild SARS-CoV-2 infection during pregnancy | Susan Pereira Ribeiro, Emory University, Atlanta, GA, USA
   
 
  • Artificial intelligence predicts severity of COVID-19 based on correlation of exaggerated monocyte activation, excessive organ damage and hyperinflammatory syndrome | Olga Vershinina , Institute of Information Technology, Mathematics and Mechanics, National Research Lobachevsky State University of Nizhniy Novgorod, Russia
   
 
  • Novel CRISPR-Cas13d system to target highly conserved sequences of SARS-CoV-2 and other human coronaviruses | Mouraya Hussein, University of Amsterdam, Amsterdam, The Netherlands
   
 
  • Investigation of nosocomial outbreaks of SARS-CoV-2 at a University Hospital using whole genome sequencing | Laurens Lambrechts, Ghent University, Ghent, Belgium
   
10.20 - 10.45 Break and posterviewing
   

COVID-19 VACCINATION

Chaired by Sarah Gerlo & Bert Schepens
10.45 - 11.10 Response of SARS-CoV-2 vaccination towards variants
Steven Callens, Ghent University Hospital, Ghent, Belgium
Q&A
   
11.10 - 11.35 Antibody-based treatments to prevent and tackle SARS-CoV-2 infections
Delphine Acar, Ghent University Hospital, Ghent, Belgium
Q&A
   
11.35 - 12.00 Poster Presentations:
 
  • COVID-19 vaccination with BNT162b2 and ChAdOx1 vaccines has the potential to induce nasal neutralizing antibodies | Jozefien Declercq, Ghent University and VIB, Ghent, Belgium
   
 
  • COVID-19 transmission within a cluster of Belgian students: epidemiological and clinical characteristics and their implications on future response and vaccination strategies | Febe Magherman & Aron Walraevens , Ghent University, Ghent, Belgium
   
 
  • The Neutralizing Activity of convalescent plasma from patients infected with the B.1 SARS-CoV-2 strain drops against the Beta variant and is highly diverse against the other Variants of Concern | Danielle Perez Bercoff, Luxembourg Institute of Health, Esch-sur-Alzette, Luxembourg
   
 
  • Comparing anti-S1 antibody titers in cancer patients after BNT162B2 or ChAdOx1 COVID-19 vaccination | Yana Debie, University Hospital Antwerp, Edegem, Belgium
   
12.00 - 13.00 Break/Satellite Symposia
   

HIV RESERVOIR

Chaired by Jozefien De Clercq & Marion Pardons
13.00 - 13.25 Spatial Approaches to Identify and Characterize HIV Reservoirs
Jacob Estes, Oregon Health and Science University, Oregon, US
Q&A
   
13.25 - 13.50 Next generation multiplex assays for assessment of HIV intactness
Linos Vandekerckhove, Ghent University and Ghent University Hospital, Ghent, Belgium
Q&A
   
13.50 - 14.15 Poster Presentations:
 
  • Dynamics of inflammatory mediators and their clinical correlates following early treated acute HIV infection | Jozefien De Clercq, Ghent University and Ghent University Hospital, Ghent, Belgium
   
 
  • Multiplex assays in dPCR for the quantification of the HIV-1 reservoir | Willem Van Snippenberg, Ghent University, Ghent, Belgium
   
 
  • Chimeric proviral/human transcription events at the bach2 integration locus in cellular models for chronic HIV infection | Ulrike Lange, University Medical Center Hamburg-Eppendorf, Hamburg, Germany
   
14.15 - 14.30 Break and posterviewing
   

HIV CURE

Chaired by Wojciech Witkowski & Jolien Van Cleemput
14.30 - 14.55 The use of bNAbs towards an HIV cure
Sarah Fidler, Imperial College London, London, UK
Q&A
   
14.55 - 15.20 Engineering the immune system for HIV Cure
Paula Cannon, University of Southern California, California, US
Q&A
   
15.20 - 15.45 Poster Presentations:
 
  • Novel NK activating multimeric immunotherapeutic compleXes (NaMix) induce cytotoxic activity against HIV-1 infected cells in vitro and in vivo | Carole Devaux, Luxembourg Institute of Heatlh, Esch-sur Alzette, Luxembourg
         
 
  • HYBRID CAR-T cell secreted antibodies neutralize HIV | Wojciech Witkowski, Ghent University, Ghent, Belgium
   
 
  • Real-life patient-reported outcomes among people living with HIV on single- versus multi-tablet regimens | Sophie Degroote, Ghent University Hospital, Ghent, Belgium
   
15.45 - 16.00 Closing 
  Linos Vandekerckhove, Ghent University and Ghent University Hospital, Ghent, Belgium